Aduro BioTech Inc (NASDAQ:ADRO) – Stock analysts at Svb Leerink issued their Q1 2019 EPS estimates for Aduro BioTech in a research report issued to clients and investors on Monday, April 15th. Svb Leerink analyst D. Graybosch expects that the biotechnology company will earn ($0.03) per share for the quarter. Svb Leerink currently has a “Outperform” rating and a $9.00 target price on the stock. Svb Leerink also issued estimates for Aduro BioTech’s Q3 2019 earnings at $0.21 EPS, FY2019 earnings at ($0.19) EPS, FY2020 earnings at ($1.12) EPS, FY2021 earnings at ($0.37) EPS, FY2022 earnings at ($1.86) EPS and FY2023 earnings at $0.24 EPS.
Several other brokerages have also commented on ADRO. Oppenheimer reissued a “buy” rating on shares of Aduro BioTech in a report on Tuesday, March 19th. BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a report on Friday, March 29th. Leerink Swann started coverage on Aduro BioTech in a report on Monday. They issued an “outperform” rating on the stock. Zacks Investment Research upgraded Aduro BioTech from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Wednesday, December 19th. Finally, HC Wainwright restated a “buy” rating and issued a $8.30 target price on shares of Aduro BioTech in a research report on Wednesday, December 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $7.68.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.10). Aduro BioTech had a negative net margin of 632.05% and a negative return on equity of 54.84%.
Large investors have recently bought and sold shares of the business. Federated Investors Inc. PA raised its position in Aduro BioTech by 268.3% in the third quarter. Federated Investors Inc. PA now owns 10,331 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 7,526 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Aduro BioTech by 138.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,402 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 7,202 shares during the period. Virtu Financial LLC purchased a new stake in Aduro BioTech in the fourth quarter valued at $38,000. SG Americas Securities LLC purchased a new stake in Aduro BioTech in the fourth quarter valued at $42,000. Finally, Cobblestone Capital Advisors LLC NY purchased a new stake in Aduro BioTech in the fourth quarter valued at $56,000. Institutional investors own 44.82% of the company’s stock.
In other Aduro BioTech news, CFO Jennifer Lew sold 18,601 shares of Aduro BioTech stock in a transaction on Monday, April 8th. The stock was sold at an average price of $4.07, for a total value of $75,706.07. Following the sale, the chief financial officer now owns 139,380 shares in the company, valued at $567,276.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Elsas Andrea Van sold 6,844 shares of Aduro BioTech stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $4.25, for a total value of $29,087.00. Following the completion of the sale, the insider now owns 245,638 shares in the company, valued at approximately $1,043,961.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,526 shares of company stock worth $128,874. 5.20% of the stock is currently owned by company insiders.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Featured Story: What is the Rule of 72?
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.